State of the Biopharmaceutical Industry 2026 Edition

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The biopharmaceutical industry is entering 2026 against a backdrop of heightened uncertainty, shaped by macroeconomic volatility, geopolitical tension, regulatory change, and rapid technological evolution. While the sector is often viewed as relatively resilient during economic downturns, it continues to face mounting pressure from pricing and reimbursement constraints, regulatory reform, supply chain disruption, and intensifying demands to innovate sustainably.

At the same time, emerging technologies such as artificial intelligence, automation, and personalized medicine are redefining how biopharmaceutical companies operate across the value chain. These technologies offer pathways to greater efficiency and innovation, but also introduce new complexity as companies balance cost pressures, regulatory scrutiny, and shifting global policy priorities.

GlobalData’s State of the Biopharmaceutical Industry report examines the business environment, trends, and challenges expected to shape the industry over the next 12 months. Drawing on survey data from pharmaceutical professionals, the report provides a grounded, forward-looking view of which themes will have the greatest positive and negative impact on industry performance in 2026.

Scope

This report benchmarks the impact of major themes shaping the biopharmaceutical industry over the next 12 months, including:

  • Assessment of emerging technologies, regulatory trends, macroeconomic trends, and industry dynamics

  • Identification of themes expected to have the greatest positive or negative impact

  • Capture and analysis of expert opinions from pharmaceutical industry professionals

  • Evaluation of industry growth prospects for the next 12 months

How industry leaders are using this report

Biopharmaceutical executives, strategy teams, and market intelligence professionals use this report to:

  • Understand how macroeconomic, regulatory, and technological forces are converging to shape industry performance.
  • Assess near-term risks and opportunities linked to pricing, reimbursement, and policy reform.
  • Benchmark sentiment and expectations across the global biopharmaceutical industry.
  • Inform strategic planning, portfolio decisions, and investment prioritization for 2026.
  • Anticipate shifts in funding, collaboration, and geographic investment focus.

Key Highlights

This report highlights the most important trends and sentiment shaping the biopharmaceutical industry outlook, including:

  • Artificial intelligence, immuno-oncology, rising clinical trial costs, and personalized and precision medicine rated as the most impactful emerging industry trends for the next 12 months.
  • Surveyed pharmaceutical professionals identifying AI across the pharma value chain, delays in revenue generation due to pricing and reimbursement processes, and supply chain challenges as the trends with the greatest industry impact.
  • Regulatory and macroeconomic actions linked to the Trump administration ranked as both the most positive and the most negative emerging trend, highlighting deep uncertainty around policy direction.
  • Growing pressure on drug pricing from most-favored-nation (MFN) pricing and drug price constraints under the Inflation Reduction Act (IRA).
  • Strong belief among respondents that collaboration with China will continue, with many viewing partnerships as an ongoing opportunity.
  • 52% of respondents reporting optimistic or very optimistic sentiment about the biopharmaceutical industry’s growth prospects in 2026.
  • Improving outlook for biotech funding recovery, with 39% of respondents optimistic or very optimistic for the next 12 months, up from 24% in May 2026.
  • Increased competitive pressure from biosimilars, with price linkage requirements expected to reduce prices for both originator products and biosimilars.
  • Expectation that the EU and US will attract the most investment in the next 12 months, followed by the EU and China.
  • Top-selling drugs for 2026 forecast to include Eli Lilly’s Mounjaro, rising from sixth to third place, and Novo Nordisk’s Wegovy, entering the top 10 at eighth place.

Reasons to Buy

This report enables you to:

  • Gain a clear understanding of the business environment facing the biopharmaceutical industry.
  • Analyze how major industry, regulatory, and macroeconomic themes will affect the sector in the next 12 months.
  • Identify which trends are likely to have the most positive or negative impact in the near term.
  • Understand industry sentiment toward growth, funding recovery, and collaboration opportunities.
  • Support informed decision-making with data-driven, forward-looking analysis.

Who should buy this report

  • Biopharmaceutical and Pharmaceutical Companies
  • Biotechnology Firms
  • Strategy, Market Intelligence, and Competitive Intelligence Teams
  • Regulatory, Market Access, and Policy Teams
  • Investors and Corporate Development Teams
  • Consultants and Industry Advisors

Table of Contents

Executive Summary

Study Design

Emerging Industry Trends

Emerging Regulatory and Macroeconomic Trends

Policies and Regulations

Emerging Technologies

Industry’s Growth Prospects

Watch Outs

Summary of Key Findings

Appendix

Authors and Contributors

Contact Us

State of the Biopharmaceutical Industry 2026 Edition thematic reports
Currency USD
$4,950

Can be used by individual purchaser only

$14,850

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

State of the Biopharmaceutical Industry 2026 Edition was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Pharmaceuticals
New
Catalyst Monitor: Q1 2026 Outlook
$1,870 | December 2025
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at State of the Biopharmaceutical Industry 2026 Edition in real time.

  • Access a live State of the Biopharmaceutical Industry 2026 Edition dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.